BIIB
Undervalued by 25.8% based on the discounted cash flow analysis.
Market cap | $29.48 Billion |
---|---|
Enterprise Value | $34.94 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $7.97 |
Beta | 0.0 |
Outstanding Shares | 145,596,895 |
Avg 30 Day Volume | 1,281,050 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 25.39 |
---|---|
PEG | 1790.52 |
Price to Sales | 3.24 |
Price to Book Ratio | 2.05 |
Enterprise Value to Revenue | 3.62 |
Enterprise Value to EBIT | 18.55 |
Enterprise Value to Net Income | 29 |
Total Debt to Enterprise | 0.19 |
Debt to Equity | 0.43 |
No data
No data
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...